<DOC>
	<DOCNO>NCT00002259</DOCNO>
	<brief_summary>To study toxicity efficacy IV mitoxantrone hydrochloride ( Novantrone ) AIDS-related Kaposi 's sarcoma .</brief_summary>
	<brief_title>Phase II Study Intravenous Novantrone ( R ) Treatment AIDS Related Kaposi 's Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : Biopsy prove Kaposi 's sarcoma advance stage . Positive HIV antibody , HIV culture antigen capture T4 cell &lt; 500 patient AIDS risk factor . Informed consent availability followup . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Uncontrolled opportunistic infection . Any medical , surgical psychiatric condition would constitute contraindication use mitoxantrone . Concurrent Medication : Excluded : Zidovudine ( AZT ) . Patients follow exclude : Uncontrolled opportunistic infection . Unable give inform consent . Any medical , surgical psychiatric condition would constitute contraindication use mitoxantrone . Prior Medication : Excluded : More one form chemotherapy regimen . Doxorubicin therapy &gt; 300 mg/m2 . Prior Treatment : Excluded : Previous therapy consist one modality therapy ( e.g. , chemotherapy plus radiotherapy one form chemotherapy regimen . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1991</verification_date>
	<keyword>Mitoxantrone</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>